IP Verse

Il-15R Alpha Forms, Cells Expressing Il-15R Alpha Forms, And Therapeutic Uses Of Il-15R Alpha And Il-15/Il-15R Alpha Complexes - EP2911684

The patent EP2911684 was granted to Admune Therapeutics on Jun 19, 2019. The application was originally filed on Oct 23, 2013 under application number EP13849581A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2911684

ADMUNE THERAPEUTICS
Application Number
EP13849581A
Filing Date
Oct 23, 2013
Status
Granted And Under Opposition
May 17, 2019
Grant Date
Jun 19, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GRAF VON STOSCHMar 19, 2020GRAF VON STOSCHWITHDRAWN

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20060758819-
DESCRIPTIONUS20060812566-
DESCRIPTIONGB2034323
DESCRIPTIONUS2005048549
DESCRIPTIONUS4675187
DESCRIPTIONUS4889803
DESCRIPTIONUS5965726
DESCRIPTIONUS6162432
DESCRIPTIONUS6174666
DESCRIPTIONUS6291664
DESCRIPTIONUS6414132
DESCRIPTIONUS6794498
DESCRIPTIONUS8124084
DESCRIPTIONUS8163879
DESCRIPTIONUS8507222
DESCRIPTIONWO0168882
DESCRIPTIONWO02069904
DESCRIPTIONWO02098370
DESCRIPTIONWO2005085282
DESCRIPTIONWO2007070488
DESCRIPTIONWO2007084342
DESCRIPTIONWO2010020047
DESCRIPTIONWO9308656
DESCRIPTIONWO9412650
DESCRIPTIONWO9530695
INTERNATIONAL-SEARCH-REPORTUS2007160578
INTERNATIONAL-SEARCH-REPORTUS2009082299
INTERNATIONAL-SEARCH-REPORTUS2009238791
INTERNATIONAL-SEARCH-REPORTUS2011081311
OPPOSITIONUS2007160578
SEARCHWO2008143794
SEARCHWO2011020047

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Darrell J Irvine, Et Al, "Routes of Delivery for Biological Drug Products", Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development and Manufacturing, (20100101), pages 1 - 50, Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development and Manufacturing, (20200701), XP055710714-
OPPOSITION- DUBOIS SIGRID, ET AL, "Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8(+)/CD44(high) T cells and its antitumor action", The Journal of Immunology, American Association of Immunologists, US, US, (20080201), vol. 180, no. 4, ISSN 0022-1767, pages 2099 - 2106, XP002582129-
OPPOSITION- Elaine Radwanski, Et Al, "Pharmacokinetics and Leukocyte Responses of Recombinant Human Interleukin-10", Pharmaceutical Research, (19980101), pages 1895 - 1901, Pharmaceutical Research, URL: https://link.springer.com/content/pdf/10.1023/A:1011918425629.pdf, (20200702), XP055710950-
OPPOSITION- Gijsbert De Gast, Et Al, "Phase I Trial of Combined Immunotherapy with Subcutaneous Granulocyte Macrophage Colony-stimulating Factor, Low-Dose Interleukin 2, and Interferon α in Progressive Metastatic Melanoma and Renal Cell Carcinoma", Clinical Cancer Research, American Association for Cancer Research, United States, United States, (20000401), pages 1267 - 1272, Clinical Cancer Research, URL: https://clincancerres.aacrjournals.org/content/clincanres/6/4/1267.full.pdf, (20200702), XP055710964-
OPPOSITION- BERGAMASCHI et al., "Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques", Cytokine, (20180000), vol. 108, doi:10.1016/j.cyto.2018.01.011, pages 213 - 224, XP085399105
OPPOSITION- Anne Bessard, V�ronique Sol�, Gr�gory Bouchaud, Agn�s Qu�m�ner, Yannick Jacques, "High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US, (20090901), vol. 8, no. 9, doi:10.1158/1535-7163.MCT-09-0275, ISSN 1535-7163, pages 2736 - 2745, XP002636846
OPPOSITION- J Weber, Et Al, "Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies", Journal of Clinical Oncology, (19930101), vol. 11, no. 3, pages 499 - 506, XP055710975
OPPOSITION- Richter Wolfgang F.; Bhansali Suraj G.; Morris Marilyn E., "Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration", The AAPS Journal, Springer US, Boston, Boston, (20120523), vol. 14, no. 3, doi:10.1208/s12248-012-9367-0, pages 559 - 570, XP035719285
SEARCH- E. CHERTOVA ET AL, "Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15{middle dot}IL-15R Cytokine Compared to IL-15 Monomer", JOURNAL OF BIOLOGICAL CHEMISTRY, (20130506), vol. 288, no. 25, doi:10.1074/jbc.M113.461756, ISSN 0021-9258, pages 18093 - 18103, XP055134195 [YP] 1-4,11,12,15 * the whole document *
SEARCH- C. BERGER ET AL, "Safety and immunologic effects of IL-15 administration in nonhuman primates", BLOOD, US, (20090917), vol. 114, no. 12, doi:10.1182/blood-2008-12-189266, ISSN 0006-4971, pages 2417 - 2426, XP055252042 [Y] 1-4,11,12,15 * the whole document *
SEARCH- T. A. WALDMANN ET AL, "Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques", BLOOD, US, (20110505), vol. 117, no. 18, doi:10.1182/blood-2010-10-311456, ISSN 0006-4971, pages 4787 - 4795, XP055251912 [Y] 1-4,11,12,15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents